English
The Health Sciences Authority (HSA) of Singapore has updated its guidance documents for Cell, Tissue and Gene Therapy Products (CTGTP), reflecting the continued development of Singapore’s regulatory framework for advanced therapies.
According to HSA, Cell, Tissue and Gene Therapy Products are regulated in Singapore in relation to registration, import, manufacture and supply. The updated guidance documents are designed to help companies meet regulatory requirements when developing, registering, manufacturing or managing changes to CTGTPs in Singapore.
This update is highly relevant to cell therapy developers, gene therapy companies, regenerative medicine organisations, CDMOs, clinical trial sponsors and quality teams working with advanced therapy products.
Key Documents Updated by HSA
The HSA CTGTP guidance documents page includes regulatory guidance, forms and templates covering product notification, registration, variation applications, GMP, GDP, post-market surveillance and product recall.
Two important CTGTP documents were marked as updated on 23 June 2026:
CMC Requirements for CTGTP for Clinical Trials and Product Registration
Guidance on CTGTP Registration and Variation Applications in Singapore
These documents are particularly relevant for companies preparing clinical trial applications, product registration submissions, or post-approval change applications for Class 2 CTGTPs.
For advanced therapy developers, Chemistry, Manufacturing and Controls (CMC) requirements are a critical part of regulatory submissions. CTGTPs are often complex biological products involving living cells, tissues, genetic modification, viral vectors, or highly controlled manufacturing processes. Therefore, regulators generally expect clear documentation of starting materials, manufacturing steps, process controls, analytical methods, sterility assurance, product characterisation and batch consistency.
Why This Matters for Cell and Gene Therapy Developers
Cell and gene therapy products are highly sensitive to process variation. Unlike conventional small-molecule drugs, CTGTPs often depend on biological starting materials, controlled cell expansion, aseptic processing and strict chain-of-identity or chain-of-custody management.
For companies moving from early research to clinical trials or commercial registration, the updated HSA documents may help clarify how quality, manufacturing and registration information should be prepared.
Key areas of attention may include:
Product classification and registration pathway
CMC data for clinical trials and product registration
Manufacturing process description
Control of raw materials and critical materials
Cell substrate or tissue source information
Viral vector or genetic modification controls, where applicable
Sterility, endotoxin and adventitious agent testing
Batch analysis and release specifications
Stability data and storage conditions
Variation management after product approval
These areas are closely connected to the way cell and gene therapy products are developed and manufactured. They also show why high-quality, traceable and consistent materials are important throughout the product lifecycle.
Connection to Cell Culture Consumables
Although the HSA guidance focuses on regulatory requirements for CTGTPs, it also reinforces the broader importance of manufacturing control and material consistency in advanced therapy development.
Cell culture consumables play an important role in upstream research, process development, clinical manufacturing support and scale-up. Products such as cell culture flasks, cell factories, roller bottles, Erlenmeyer shake flasks and media bottles may be used during different stages of cell expansion, seed preparation, process optimisation or supporting laboratory workflows.
For CTGTP developers, reliable cell culture conditions are essential. Variability in culture vessels, surface treatment, sterility, material quality or batch consistency can affect cell growth, attachment, morphology, viability and process repeatability.
This is especially important for:
Stem cell and MSC expansion
Immune cell therapy development
Viral vector production support
Exosome and extracellular vesicle research
Regenerative medicine process development
Cell-based assay and quality control workflows
When regulatory expectations place more emphasis on CMC, GMP, traceability and change control, manufacturers need to evaluate not only their core process but also the consumables and materials used across development and production.
Importance of Quality and Traceability
For companies developing CTGTPs, regulatory readiness depends on more than product innovation. It also depends on a strong quality system and well-documented manufacturing environment.
Consistent cell culture consumables can help reduce unnecessary process variability. For example, sterile production, batch traceability, DNase/RNase-free status, endotoxin control, material qualification and reliable supply are all factors that support quality-driven development.
In advanced therapy manufacturing, every material used in the process may become part of the broader quality discussion. This is why suppliers of cell culture consumables need to support customers with clear product specifications, stable production capability and quality documentation.
For developers preparing clinical trial or registration submissions, selecting qualified consumables early can help support smoother scale-up and reduce the risk of process changes later.
Industry Outlook
Singapore has become an important hub for biomedical innovation, advanced therapy development and biopharmaceutical manufacturing in Asia. The update of HSA’s CTGTP guidance documents reflects the growing regulatory maturity of the region’s cell and gene therapy sector.
For companies developing cell, tissue and gene therapy products, the message is clear: innovation must be supported by robust CMC data, controlled manufacturing processes and reliable quality systems.
As the CTGTP industry continues to grow, demand for sterile, traceable and batch-consistent cell culture consumables is expected to remain strong. From early-stage R&D to clinical manufacturing, reliable consumables can help advanced therapy developers build more reproducible and compliant workflows.
Source
Source: Health Sciences Authority (HSA), Singapore — “Guidance documents for CTGTP.”
The HSA CTGTP guidance documents page was last updated on 23 June 2026. The page lists updated documents including “CMC Requirements for CTGTP for Clinical Trials and Product Registration” and “Guidance on CTGTP Registration and Variation Applications in Singapore.”
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.